S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
Log in
(Ad)
2020 could be a monster year for cannabis stocks, especially with cannabis on many November ballots, and presidential candidates pushing for approval. In our latest special report, we detail five must-own cannabis stocks that could double, even triple your investment over the next year.

NASDAQ:PDEX - Pro-Dex Stock Price, Forecast & News

$16.50
-0.43 (-2.54 %)
(As of 01/23/2020 04:00 PM ET)
Today's Range
$16.24
Now: $16.50
$17.07
50-Day Range
$14.75
MA: $16.56
$17.95
52-Week Range
$10.37
Now: $16.50
$18.16
Volume5,357 shs
Average Volume10,190 shs
Market Capitalization$65.55 million
P/E Ratio17.74
Dividend YieldN/A
Beta1.56
Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PDEX
CUSIPN/A
Phone949-769-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.17 million
Cash Flow$1.06 per share
Book Value$4.14 per share

Profitability

Net Income$4.15 million

Miscellaneous

Employees80
Market Cap$65.55 million
Next Earnings Date2/6/2020 (Estimated)
OptionableNot Optionable

Receive PDEX News and Ratings via Email

Sign-up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions

What is Pro-Dex's stock symbol?

Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."

How were Pro-Dex's earnings last quarter?

Pro-Dex Inc (NASDAQ:PDEX) posted its quarterly earnings data on Thursday, November, 7th. The medical instruments supplier reported $0.27 EPS for the quarter. The medical instruments supplier had revenue of $7.24 million for the quarter. Pro-Dex had a return on equity of 22.60% and a net margin of 14.19%. View Pro-Dex's Earnings History.

When is Pro-Dex's next earnings date?

Pro-Dex is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Pro-Dex.

What price target have analysts set for PDEX?

1 brokerages have issued 12-month target prices for Pro-Dex's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Pro-Dex's stock price to reach $20.00 in the next year. This suggests a possible upside of 21.2% from the stock's current price. View Analyst Price Targets for Pro-Dex.

What is the consensus analysts' recommendation for Pro-Dex?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pro-Dex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pro-Dex.

Has Pro-Dex been receiving favorable news coverage?

Press coverage about PDEX stock has been trending extremely positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pro-Dex earned a news impact score of 4.4 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Pro-Dex.

Are investors shorting Pro-Dex?

Pro-Dex saw a decrease in short interest in December. As of December 31st, there was short interest totalling 9,800 shares, a decrease of 20.3% from the December 15th total of 12,300 shares. Based on an average trading volume of 15,800 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.4% of the shares of the stock are short sold. View Pro-Dex's Current Options Chain.

Who are some of Pro-Dex's key competitors?

What other stocks do shareholders of Pro-Dex own?

Who are Pro-Dex's key executives?

Pro-Dex's management team includes the folowing people:
  • Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 58)
  • Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 49)

Who are Pro-Dex's major shareholders?

Pro-Dex's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.29%). Company insiders that own Pro-Dex stock include Alisha Charlton, David Hovda, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot and William James Farrell III. View Institutional Ownership Trends for Pro-Dex.

Which institutional investors are selling Pro-Dex stock?

PDEX stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. Company insiders that have sold Pro-Dex company stock in the last year include Alisha Charlton, David Hovda and Raymond E Cabillot. View Insider Buying and Selling for Pro-Dex.

How do I buy shares of Pro-Dex?

Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pro-Dex's stock price today?

One share of PDEX stock can currently be purchased for approximately $16.50.

How big of a company is Pro-Dex?

Pro-Dex has a market capitalization of $65.55 million and generates $27.17 million in revenue each year. Pro-Dex employs 80 workers across the globe.View Additional Information About Pro-Dex.

What is Pro-Dex's official website?

The official website for Pro-Dex is http://www.pro-dex.com/.

How can I contact Pro-Dex?

Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected]


MarketBeat Community Rating for Pro-Dex (NASDAQ PDEX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Golden Cross

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel